tirzepatide clinical trial weight loss results Semaglutide vs Tirzepatide: Which GLP-1 Wins for Loss? Before and after tirzepatide weight

According to a JAMA clinical trial, GLP-1 receptor agonists, including Ozempic (semaglutide), liraglutide, and dulaglutide, have been linked to an increased risk of gallbladder and biliary diseases, such as gallstones and gallbladder inflammation

Theyre acting on the system that makes you want the cake, not just the system that makes you feel full. The findings also help explain differences among drugs in this rapidly growing class

doi: 10.1038/ijo.2013.120 94 BodeB

The Asia Pacific GLP-1 market is projected to witness the fastest growth during the forecast period, owing to the rapid rise in lifestyle-related diseases and improving healthcare access

Keep a water bottle in sight and sip through the day